Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 1, 2012, Pages 406-412

  Adamus, Grazyna ^a   Brown, Lori ^a   Andrew, Shayne ^b   Meza Romero, Roberto ^b   Burrows, Gregory G ^b,c,d   Vandenbark, Arthur A ^b,d,e  

^a CASEY EYE INSTITUTE   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c Departments of Biochemistry   (United States)

^d Departments of Neurology   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN; RECOMBINANT T LYMPHOCYTE RECEPTOR; RTL342M; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; GLYCOPROTEIN; HLA DRB1 ANTIGEN; HLA DRB1*15:01 ANTIGEN; HLA-DRB1*15:01 ANTIGEN; HYBRID PROTEIN; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35 55); MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); PEPTIDE FRAGMENT; RTL342M PROTEIN, MOUSE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DEMYELINATION; FEMALE; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; IMMUNOTHERAPY; INFLAMMATORY CELL; MALE; MOUSE; NERVE FIBER; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; OPTIC NEURITIS; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETINA GANGLION CELL; TRANSGENIC MOUSE; ANIMAL; CHEMICALLY INDUCED DISORDER; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; METABOLISM; MYELIN SHEATH; PATHOLOGY; TRANSGENE;

ANIMALS; AXONS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLYCOPROTEINS; HLA-DRB1 CHAINS; IMMUNOTHERAPY; LIGANDS; MALE; MICE; MICE, TRANSGENIC; MYELIN SHEATH; OPTIC NEURITIS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RETINAL GANGLION CELLS; TRANSGENES;

EID: 84859253143     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8419     Document Type: Article

References (36)

1. Margalit E, Sadda SR. Retinal and optic nerve diseases. Artif Organs. 2003;27:963-974.
2. Balcer LJ. Clinical practice: optic neuritis. N Engl J Med. 2006;354: 1273-1280.
3. Pau D, Al Zubidi N, Yalamanchili S, Plant GT, Lee AG. Optic neuritis. Eye. 2011;25:833-842.
4. Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology. 2006;67:258-262.
5. Shams PN, Plant GT. Optic neuritis: a review. Int MS J. 2009;16: 82-89.
6. Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005;139:1101-1108.
7. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121:944-949.
8. Volpe NJ. The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results. Arch Ophthalmol. 2008;126:996-999.
9. The Optic Neuritis Study Group: Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65:727-732.
10. Francis DA, Compston DA, Batchelor JR, McDonald WI. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry. 1987;50:758-765.
11. Furlan R, Cuomo C, Martino G. Animal models of multiple sclerosis. Methods Mol Biol. 2009:157-173.
12. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247-269.
13. Rich C, Link JM, Zamora A, et al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol. 2004;34:1251-1261.
14. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med. 2003;197:1073-1081.
15. Chang JW, Mechling DE, Bachinger HP, Burrows GG. Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2. J Biol Chem. 2001;276:24170-24176.
16. Offner H, Sinha S, Wang C, Burrows GG, Vandenbark AA. Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis. Rev Neurosci. 2008;19:327-339.
17. Offner H, Sinha S, Burrows GG, Ferro AJ, Vandenbark AA. RTL therapy for multiple sclerosis: a phase I clinical study. J Neuroimmunol. 2011;231:7-14.
18. Burrows GG. Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands. Curr Drug Targets Inflamm Allergy. 2005;4:185.
19. Link JM, Rich CM, Korat M, Burrows GG, Offner H, Vandenbark AA. Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice. Clin Immunol. 2007;123:95-104.
20. Vandenbark AA, Rich C, Mooney J, et al. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J Immunol. 2003;171:127-133.
21. Sinha S, Subramanian S, Proctor TM, et al. A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS. J Neurosci. 2007;27:12531-12539.
22. Grider MH, Chen Q, Shine HD. Semi-automated quantification of axonal densities in labeled CNS tissue. J Neurosci Meth. 2006;155: 172-179.
23. Hobom M, Storch MK, Weissert R, et al. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol. 2004;14:148-157.
24. Guan Y, Shindler KS, Tabuena P, Rostami AM. Retinal ganglion cell damage induced by spontaneous autoimmune optic neuritis in MOG-specific TCR transgenic mice. J Neuroimmunol. 2006;178: 40-48.
25. Shindler KS, Ventura E, Dutt M, Rostami A. Inflammatory demyelination induces axonal injury and retinal ganglion cell apoptosis in experimental optic neuritis. Exp Eye Res. 2008;87:208-213.
26. McConnell P, Berry M. Regeneration of axons in the mouse retina after injury. Bibl Anat 1982;(23):26-37.
27. Dutt M, Tabuena P, Ventura E, Rostami A, Shindler KS. Timing of corticosteroid therapy is critical to prevent retinal ganglion cell loss in experimental optic neuritis. Invest Ophthalmol Vis Sci. 2010;51:1439-1445.
28. Touil T, Ciric B, Ventura E, Shindler KS, Gran B, Rostami A. Bowman-Birk inhibitor suppresses autoimmune inflammation and neuronal loss in a mouse model of multiple sclerosis. J Neurolog Sci. 2008;271:191-202.
29. Qi X, Sun L, Lewin AS, Hauswirth WW, Guy J. Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy. Invest Ophthalmol Vis Sci. 2007;48: 5360-5370.
30. Chaudhary P, Marracci G, Yu X, Galipeau D, Morris B, Bourdette D. Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis. J Neuroimmunol. 2011; 233:90-96.
31. Burrows GG, Chang JW, Bachinger HP, Bourdette DN, Offner H, Vandenbark AA. Design, engineering and production of functional single-chain T cell receptor ligands. Protein Eng. 1999;12:771-778.
32. Adamus G, Burrows GG, Vandenbark AA, Offner H. Treatment of autoimmune anterior uveitis with recombinant TCR Ligands, Invest Ophthalmol Vis Sci. 2006;47:2555-2561.
33. Adamus G, Karren L, Mooney J, Burrows G. A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis, Ophthalmic Res. 2010;44:24-33.
34. Huan J, Kaler LJ, Mooney JL, Subramanian S, et al. MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis. J Immunol. 2008;180:1249-1257.
35. Klistorner A, Arvind H, Garrick R, Yiannikas C, Paine M, Graham SL. Remyelination of optic nerve lesions: spatial and temporal factors. Multiple Sclerosis. 2010;16:786-795.
36. Wang C, Gold BG, Kaler LJ, et al. Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem. 2006;98:1817-1827.